Skip to main content
. Author manuscript; available in PMC: 2017 Apr 1.
Published in final edited form as: Clin Lymphoma Myeloma Leuk. 2015 Dec 23;16(4):203–212. doi: 10.1016/j.clml.2015.12.005

Figure 8. Enhancing viral host-protein shut-off improves MYXV’s oncolytic efficacy.

Figure 8

(A) Human U266 MM cells were either mock-treated or infected with vMYX-GFP or vMYX-ΔM083 at the indicated MOIs. Two hours post-infection, cells were harvested and the expression of the indicated proteins was analyzed using immunoblot. Human U266 MM cells were infected with either vMYX-GFP or vMYX-ΔM083 at the indicated MOIs. (B) Cellular viability or (C) GFP expression was analyzed after 24 hours.